Genewish Gene TOF 3100 Biomass Spectrometry System for Nucleic Acid Analysis

Overview

The Genewish Gene TOF 3100 Biomass Spectrometry System is a purpose-built, clinical-grade time-of-flight mass spectrometer engineered for high-precision nucleic acid analysis in regulated molecular diagnostic environments. It operates on the MALDI-TOF principle: after locus-specific PCR amplification and shrimp alkaline phosphatase (SAP) treatment, extension primers are added and extended by a single base complementary to the SNP site; the resulting extension products are crystallized with a UV-absorbing matrix and ionized via pulsed nitrogen laser. Mass-to-charge (m/z) ratios of the extension products are resolved with sub-Da resolution, enabling unambiguous discrimination of single-nucleotide variants—including A/T/G/C substitutions—based solely on intrinsic molecular mass differences. This label-free, amplification-coupled MS detection eliminates dependence on fluorescent dyes, hybridization probes, or enzymatic reporters, thereby reducing assay complexity and consumable cost while maintaining analytical rigor required for IVD use.

Key Features

• High-multiplex capability: Simultaneous interrogation of up to 40+ genetic targets per well via multiplex PCR followed by single-base extension (SBE) and MALDI-TOF readout.
• Single-base resolution: Capable of distinguishing nucleotide variants differing by only 9–16 Da (e.g., dA vs. dT), delivering >99.5% genotyping concordance against orthogonal sequencing methods under ISO 15189-aligned validation protocols.
• Label-free detection architecture: No requirement for fluorophores, quenchers, or secondary enzymatic reactions—reducing reagent cost per data point and eliminating spectral overlap or probe-design constraints.
• High-throughput automation: Integrated robotic liquid handler and automated MALDI target spotting module support full 384-well plate processing; system throughput exceeds 3,000 genotype calls per 24-hour cycle under standard run conditions.
• End-to-end workflow integration: Includes validated DNA extraction kits, multiplex PCR master mixes, SBE reagents, MALDI matrices, consumable chips, and instrument control software—all qualified for routine clinical laboratory use.

Sample Compatibility & Compliance

The Gene TOF 3100 accepts purified genomic DNA from whole blood, saliva, buccal swabs, FFPE tissue extracts, and plasma-derived cell-free DNA (cfDNA), provided input meets minimum concentration (≥5 ng/μL) and purity (A260/A280 ≥ 1.7) specifications. All onboard assays are developed and verified per CNAS-CL01:2018 (equivalent to ISO/IEC 17025) and aligned with GB/T 29791.3–2013 (Chinese technical requirements for IVD mass spectrometry systems). The platform supports audit-ready operation under GLP and GMP-aligned quality management systems, with optional electronic signature and 21 CFR Part 11–compliant data integrity modules available via software upgrade.

Software & Data Management

The proprietary Genewish SpectraView™ Suite provides instrument control, real-time spectral acquisition, automated peak detection, allele calling, cluster visualization, and QC metric reporting (including signal-to-noise ratio, peak width at half-height, and internal calibration stability). Raw spectra (.spc) and processed result files (.csv, .xlsx) are stored with immutable timestamps and user-access logs. The software includes built-in LIMS interface drivers (HL7 v2.x, ASTM E1384) and supports configurable report templates compliant with Chinese CDC reporting standards and hospital EMR integration requirements. Audit trail functionality records all parameter changes, reanalysis events, and user logins—fully traceable for regulatory inspections.

Applications

• Hereditary disease screening: Multiplexed detection of pathogenic variants in GJB2 (hereditary hearing loss), HBB (β-thalassemia), SMN1 (SMA), and G6PD (glucose-6-phosphate dehydrogenase deficiency).
• Pharmacogenomics: CYP2C19*, CYP2C9*, VKORC1, SLCO1B1, and HLA-B*15:02 genotyping to guide antiplatelet therapy, warfarin dosing, statin selection, and carbamazepine safety assessment.
• Oncology applications: Hotspot mutation profiling (e.g., BRAF V600E, EGFR L858R/T790M, KRAS G12D/V) in tumor tissue and liquid biopsy specimens; methylation status assessment at key CpG islands using bisulfite-converted DNA.
• Infectious disease diagnostics: Multiplex identification of enteric pathogens (Campylobacter, Salmonella, Shigella) and respiratory viruses/bacteria (RSV, Influenza A/B, Mycoplasma pneumoniae), including macrolide and fluoroquinolone resistance markers.

FAQ

What regulatory certifications does the Gene TOF 3100 hold for clinical use in China?
The system is designed and validated in accordance with GB/T 29791.3–2013 and has received NMPA registration as a Class II IVD instrument for genetic testing applications.
Can users develop and validate custom assays on this platform?
Yes—the open assay development environment supports user-defined primer sets, extension protocols, and spectral interpretation rules, subject to internal analytical validation per CLSI EP17-A2 guidelines.
Is raw spectral data export supported for third-party bioinformatic analysis?
Yes—native .spc files and centroided peak lists (.csv) are fully exportable without licensing restrictions.
What maintenance intervals are recommended for the MALDI source and TOF detector?
Laser optics cleaning and vacuum system inspection are recommended every 6 months; detector gain calibration is performed automatically during each startup sequence.
Does the system support remote diagnostics and firmware updates?
Yes—secure TLS 1.2–encrypted remote access is available for technical support teams, with version-controlled firmware updates delivered via authenticated download portal.